BCAP29 Products

BCAP29 Full Name

B-cell receptor-associated protein 29

BCAP29 Introduction

B-cell receptor-associated protein 29 (BCAP29) is a conserved protein found in humans and other species. Structurally and functionally, BCAP29 is closely related to another well-known endoplasmic reticulum membrane protein - B-cell receptor-associated protein 31 (BAP31). Studies indicate that BCAP29 shares up to 50% sequence homology with BAP31 and possesses a similar predicted domain organization. BAP31 itself is a multifunctional chaperone protein with three transmembrane domains, an α-helical coiled-coil domain, and a C-terminal di-lysine signal typically involved in retrograde transport from the Golgi apparatus back to the endoplasmic reticulum. Due to their high homology, BCAP29 is predicted to adopt a similar topology, enabling it to stably anchor to the ER membrane and potentially interact with other proteins via its cytoplasmic domains. However, there is a critical distinction between BCAP29 and BAP31: BCAP29 lacks the caspase cleavage site present in BAP31. During apoptosis, BAP31 can be cleaved by initiator caspases such as caspase-8, generating a 20 kDa pro-apoptotic fragment (p20) that triggers mitochondrial-associated apoptotic signaling pathways. In contrast, BCAP29, lacking this site, is not directly cleaved by caspases.

Substantial evidence clearly establishes BCAP29 as an ER membrane protein that co-resides with BAP31 on the ER membrane and can form stable heterodimeric complexes. The most well-defined and thoroughly studied function of BCAP29 is its involvement in the anterograde transport of membrane proteins from the ER to the Golgi apparatus. This process constitutes the first step of the secretory pathway and is essential for all proteins destined for secretion or localization to other organelles such as the Golgi, lysosomes, or plasma membrane. The BAP31/BCAP29 complex is crucial for the efficient export of specific client proteins, including major histocompatibility complex class I molecules (MHC class I) and cellubrevin (VAMP3). In the absence of normal BAP31/BCAP29 function, these client proteins are retained in the ER and fail to enter the secretory pathway. This suggests that the BAP31/BCAP29 complex may act as a "cargo receptor" or "sorting protein," recognizing and capturing properly folded client proteins and directing them to ER exit sites (ERES), where COPII vesicles are formed.

The DUS4L-BCAP29 fusion RNA has been detected at low levels in various non-cancerous human tissues and cells but shows aberrations in certain cancers. For example, DUS4L-BCAP29 expression has been identified in gastric and prostate cancer cell lines as well as clinical samples. Gene fusions are important drivers of cancer, often producing chimeric proteins with novel functions or dysregulated activity. The specific functional consequences of the DUS4L-BCAP29 fusion event are not yet fully understood, but it may lead to dysregulated expression of BCAP29 or generate a novel protein with oncogenic activity, thereby promoting tumor initiation or progression. This finding provides direct molecular evidence linking BCAP29 to solid tumors.

Figure 1. The DUS4L–BCAP29 fusion transcript was validated in the SNU-5 cell line using RT–PCR and Sanger sequencing. (Source: Kim HP, et al. 2014)

Alternate Names for BCAP29

BCAP29
B-cell receptor-associated protein 29
BAP29
BCR-associated protein 29

• BCAP29 Antibodies
• BCAP29 Antigens

• 1. Kim HP, et al. Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis. Oncogene. 2014 Nov 20;33(47):5434-41.
  2. Paquet ME, et al. Bap29/31 influences the intracellular traffic of MHC class I molecules. J Immunol. 2004 Jun 15;172(12):7548-55.